SEC Form 4 · accession 0001127602-16-060950
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kelly A. Kramer
Director
Period of report
Aug 19, 2016
Accepted (ET)
Aug 23, 2016 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $81.00 | Aug 19, 2016 | A | 5,611 | A | — | Aug 19, 2026 | Common Stock | 5,611 | 5,611 | D |
| Restricted Stock UnitF2,F3 | — | Aug 19, 2016 | A | 1,339 | A | — | — | Common Stock | 1,339 | 1,339 | D |
Explanation of responses
- F1Options vest quarterly over the first year of service and will be fully vested on August 19, 2017
- F2Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F3100% of the restricted stock units will vest on August 19, 2017, at the end of the first year of service.